Prezista Extends HIV Suppression in Children (CME/CE)

Prezista Extends HIV Suppression in Children (CME/CE)

Children with human immunodeficiency virus (HIV) maintain viral control for 48 weeks when treated with the protease inhibitor darunavir/ritonavir (Prezista) along with an optimized background regimen, researchers reported here.

In the Darunavir in Treatment Experienced Pediatric Population (ARIEL) study, 81% of the 21 children ages 3 to 5 years were able to achieve viral suppression to undetectable limits using the 50 copies/ml assay, an increase from the 57% viral suppression rate at 24 weeks, said Avy Violari, MD, deputy executive director of the Perinatal HIV Research Unit at Chris Hani Baragwaneth Hospital, Soweto, South Africa.